Pharmacologic therapy continues to play an important role in the manag
ement of cardiac arrhythmias. Choosing an antiarrhythmic agent involve
s understanding the concepts related to arrhythmogenesis, risk stratif
ication of patients, and antiarrhythmic mechanisms as well as the phar
macokinetics and pharmacodynamics of individual antiarrhythmic agents.
This review focuses on some practical issues related to antiarrhythmi
c pharmacologic therapy with individual class I and class III antiarrh
ythmic agents currently in clinical use in the United States.